2019. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S12. DOI:https://doi.org/10.25251/skin.3.supp.12.